Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment
Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment ...
The Lancet3h
Pharmacological therapy for cerebral cavernous malformations
Symptomatic cerebral cavernous malformation is a rare disease, and affected individuals are at risk of strokes due to intracerebral haemorrhage or new non-haemorrhagic neurological deficits.
Clinical Trials Arena on MSN10h
Novartis reports Phase III efficacy and safety outcomes of SMA treatment
In this trial, the efficacy and safety of the therapy were evaluated against a sham control in treatment-naïve SMA Type 2 ...